TogoTuberculosis profile
Population  2017 7.8 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.28 (0.19–0.4) 3.6 (2.4–5.1)
Mortality (HIV+TB only) 0.12 (0.085–0.16) 1.5 (1.1–2)
Incidence  (includes HIV+TB) 3.2 (2.6–3.8) 41 (33–49)
Incidence (HIV+TB only) 0.58 (0.38–0.83) 7.5 (4.8–11)
Incidence (MDR/RR-TB)** 0.064 (0.032–0.11) 0.82 (0.41–1.3)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.18 (0.17–0.19) 0.97 (0.87–1.1) 1.2 (1–1.3)
Males 0.2 (0.19–0.21) 1.8 (1.5–2.1) 2 (1.7–2.3)
Total 0.38 (0.35–0.41) 2.8 (2.3–3.3) 3.2 (2.6–3.8)
TB case notifications, 2017  
Total cases notified 2 633
Total new and relapse 2 544
          - % tested with rapid diagnostics at time of diagnosis 13%
          - % with known HIV status 100%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 94%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (66–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.13 (0.09–0.18)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 483 18%
          - on antiretroviral therapy 454 94%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  53
(29–77)
Estimated % of TB cases with MDR/RR-TB 1.5% (0.8–2.6) 9.7% (4.5–18)  
% notified tested for rifampicin resistance 13% 92% 507
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 27, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 25, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2016 85% 2 641
Previously treated cases registered in 2016 69% 208
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015   0
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
45% (42–50)
TB financing, 2018  
National TB budget (US$ millions) <1
Funding source: 28% domestic, 72% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data